Healthcare provider profile · identity verified

Nasser Azeez, M.D.

Family Practice · NOVI, MI · NPI 1750556999

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	812	229
Amlodipine Besylate	Amlodipine Besylate	623	167
Losartan Potassium	Losartan Potassium	443	129
Lisinopril	Lisinopril	328	96
Levothyroxine Sodium	Levothyroxine Sodium	301	91
Metformin Hcl	Metformin Hcl	260	70
Metoprolol Succinate	Metoprolol Succinate	258	73
Tamsulosin Hcl	Tamsulosin Hcl	246	75
Simvastatin	Simvastatin	231	65
Rosuvastatin Calcium	Rosuvastatin Calcium	227	68
Omeprazole	Omeprazole	187	57
Famotidine	Famotidine	183	62
Metoprolol Tartrate	Metoprolol Tartrate	167	48
Gabapentin	Gabapentin	149	54
Eliquis	Apixaban	142	40
Furosemide	Furosemide	128	39
Allopurinol	Allopurinol	123	32
Ipratropium Bromide	Ipratropium Bromide	122	54
Atenolol	Atenolol	120	30
Hydrochlorothiazide	Hydrochlorothiazide	109	28
Potassium Chloride	Potassium Chloride	104	27
Metformin Hcl Er	Metformin Hcl	101	27
Albuterol Sulfate Hfa	Albuterol Sulfate	95	41
Pravastatin Sodium	Pravastatin Sodium	92	26
Fluticasone Propionate	Fluticasone Propionate	90	42
Nifedipine Er	Nifedipine	90	23
Ezetimibe	Ezetimibe	88	27
Glipizide Er	Glipizide	81	20
Jardiance	Empagliflozin	81	21
Abrysvo	Rsv Vacc, Pref A And Pref B/Pf	80	80
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	74	20
Sertraline Hcl	Sertraline Hcl	72	20
Alprazolam	Alprazolam	71	29
Carvedilol	Carvedilol	67	23
Tramadol Hcl	Tramadol Hcl	67	19
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	65	17
Trazodone Hcl	Trazodone Hcl	61	21
Meloxicam	Meloxicam	58	21
Hydralazine Hcl	Hydralazine Hcl	56	15
Spironolactone	Spironolactone	56	15
Pantoprazole Sodium	Pantoprazole Sodium	54	21
Methocarbamol	Methocarbamol	53	26
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	49	14
Doxycycline Hyclate	Doxycycline Hyclate	45	42
Finasteride	Finasteride	45	15
Clopidogrel	Clopidogrel Bisulfate	44	12
Warfarin Sodium	Warfarin Sodium	44	15
Donepezil Hcl	Donepezil Hcl	41	suppressed
Glipizide	Glipizide	41	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	41	14
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	40	13
Ventolin Hfa	Albuterol Sulfate	37	19
Acetaminophen-Codeine	Acetaminophen With Codeine	35	suppressed
Pregabalin	Pregabalin	35	suppressed
Mounjaro	Tirzepatide	34	suppressed
Shingrix	Varicella-Zoster Ge/As01b/Pf	34	27
Escitalopram Oxalate	Escitalopram Oxalate	33	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	33	suppressed
Chlorthalidone	Chlorthalidone	32	suppressed
Mirtazapine	Mirtazapine	32	suppressed
Montelukast Sodium	Montelukast Sodium	30	12
Methylprednisolone	Methylprednisolone	28	27
Ozempic	Semaglutide	27	suppressed
Xarelto	Rivaroxaban	27	suppressed
Tenivac	Tetanus-Diphtheria Toxoids/Pf	26	26
Terazosin Hcl	Terazosin Hcl	26	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	25	suppressed
Duloxetine Hcl	Duloxetine Hcl	24	suppressed
Temazepam	Temazepam	24	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	24	suppressed
Tizanidine Hcl	Tizanidine Hcl	22	suppressed
Citalopram Hbr	Citalopram Hydrobromide	21	suppressed
Symbicort	Budesonide/Formoterol Fumarate	21	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	20	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	20	suppressed
Benazepril Hcl	Benazepril Hcl	19	suppressed
Boostrix Tdap	Diphth,pertuss(Acell),tet Vac	19	19
Clonazepam	Clonazepam	19	suppressed
Farxiga	Dapagliflozin Propanediol	19	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	18	suppressed
Propranolol Hcl Er	Propranolol Hcl	18	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	18	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	17	suppressed
Glimepiride	Glimepiride	17	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	17	suppressed
Prednisone	Prednisone	17	15
Primidone	Primidone	17	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	16	suppressed
Januvia	Sitagliptin Phosphate	16	suppressed
Paroxetine Hcl	Paroxetine Hcl	16	suppressed
Sildenafil Citrate	Sildenafil Citrate	16	suppressed
Colchicine	Colchicine	15	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	15	suppressed
Novolog Flexpen	Insulin Aspart	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	15	suppressed
Cephalexin	Cephalexin	14	11
Synthroid	Levothyroxine Sodium	14	suppressed
Alfuzosin Hcl Er	Alfuzosin Hcl	13	suppressed
Benzonatate	Benzonatate	13	suppressed
Labetalol Hcl	Labetalol Hcl	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	13	suppressed
Ammonium Lactate	Ammonium Lactate	12	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Diclofenac Sodium	Diclofenac Sodium	12	suppressed
Mexiletine Hcl	Mexiletine Hcl	12	suppressed
Nitroglycerin	Nitroglycerin	12	suppressed
Nystatin	Nystatin	12	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	12	12
Azelastine Hcl	Azelastine Hcl	11	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	11	suppressed
Humalog Kwikpen U-100	Insulin Lispro	11	suppressed
Methylphenidate Er	Methylphenidate Hcl	11	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error